

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

COMPLETION OF THE STATUTORY REGISTRATION AND FILING PROCEDURES OF REDUCTION OF REGISTERED CAPITAL

Reference is made to the announcement of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the “**Company**”) dated 26 May 2022 in relation to the cancellation of the repurchased H shares, reduction of registered capital and amendments to the articles of association of the Company. The Company has completed the cancellation of the 14,000,000 H shares on 7 June 2022.

The Company has completed the statutory registration and filing procedures for the capital reduction and obtained the renewed business license issued by the Shanghai Municipal Administration for Market Regulation recently. The Company’s registered capital has reduced from RMB104,300,000 to RMB102,900,000.

By Order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)
Mr. Su Yong (Executive Director)
Mr. Zhao Da Jun (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Zhou Zhong Hui (Independent Non-executive Director)
Mr. Lam Yiu Kin (Independent Non-executive Director)
Mr. Xu Qing (Independent Non-executive Director)
Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

14 July 2022

** For identification purpose only*